Printer Friendly

BIOMEDICAL SENSORS INTRODUCES THE PARATREND 7

 BIOMEDICAL SENSORS INTRODUCES THE PARATREND 7
 NEW YORK, June 24 /PRNewswire/ -- Biomedical Sensors, a unit of


Pfizer Inc (NYSE: PFE), recently introduced its new Paratrend 7 intra- vascular, continuous blood gas monitoring system at the World Congress of Anesthetists meeting at The Hague, Holland.
 The management and treatment of critically ill patients depends upon blood gas information to determine cardio-respiratory status. Physicians now take intermittent blood samples, which are analyzed at clinical laboratories. Continuous monitoring reduces valuable time in receiving vital information, allowing pro-active diagnosis and therapy. Such monitoring also reduces the number of blood samples and leads to more efficient health care.
 The Paratrend 7 is the smallest sensor available with a diameter of only 0.45mm. The small size and unique co-axial introducer allows rapid aseptic placement in the patient via a standard arterial catheter, while protecting the quality of the blood pressure measurement. The careful selection of materials and an anti-thrombogenic sensor surface treatment, ensure that it will function in-vivo for a minimum of 72 hours. Results from clinical trials show excellent correlation with laboratory analysis, and continuous sensor functioning for up to 200 hours where extended patient monitoring has been permitted.
 Biomedical Sensors will begin hospital product demonstrations and taking orders for systems, using direct sales and specialized dealer organizations, in July 1992.
 Initial introduction will be in the U.S. and U.K. Subsequent introduction is planned in the remainder of Europe, Japan and Canada.
 As a result of a six year development program backed by 14 years experience designing and manufacturing in-vivo sensor devices, Biomedical Sensors has maintained its recognized leadership in this field by producing the Paratrend 7 intra-vascular sensor, incorporating both electrochemical and fiber optic technology. The Paratrend 7 system is the first in a new series of quality innovative devices from Biomedical Sensors, serving the community's need for continuous in-vivo monitoring.
 Pfizer Inc is a research-based, diversified health care company with global operations. The company reported sales of approximately $6.95 billion for 1991.
 -0- 6/23/92
 /CONTACT: A.A. Biesada, 212-573-2055, or Rick Honey, 212-573-2051, both of Pfizer/
 (PFE) CO: Pfizer Inc ST: New York IN: MTC SU: PDT


PS -- NY058 -- 3382 06/24/92 15:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 24, 1992
Words:369
Previous Article:U.S. EPA, MARINE CORPS SETTLE TOXIC WASTE VIOLATIONS
Next Article:APPELLATE COURT UPHOLDS $1.25 MILLION VERDICT AGAINST BLUE SHIELD OF CALIFORNIA
Topics:


Related Articles
Diametrics Medical Negotiating Purchase of Pfizer's Biomedical Sensors
Diametrics Medical, Inc. Announces Record First Quarter Sales
Irvine Biomedical, Inc. Receives CE Mark for Inquiry and Therapy Electrophysiology Catheters and ISO 9002 for Its Quality System
IVY Biomedical and Masimo Corporation Announce Pulse Oximetry Purchasing and Licensing Agreement
Diametrics Medical Announces Reduced Workforce
Diametrics Completes Private Equity Placement With Hewlett-Packard; HP Invests $9.5 Million In Diametrics, Pays $7 A Share.
Diametrics Medical Names HP's Hans-Guenter Hohmann to Its Board.
Diametrics Medical and Cook Incorporated Enter Co-Development Pact to Produce Critical Care Products.
Diametrics Medical Receives FDA Clearance for Its Brain Monitoring System, Neurotrend, and New Calibration System.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters